Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 421-423

  Johnson, Philip J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHRONIC LIVER DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG LEGISLATION; EDITORIAL; ETHNOLOGY; FINANCIAL MANAGEMENT; GEOGRAPHY; GOOD CLINICAL PRACTICE; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; RELIABILITY; RISK ASSESSMENT; SAFETY;

EID: 0042510828     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.421     Document Type: Editorial

References (11)

1. European Parliament and the Council of the European Union. Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off. J. Eur. Commun. 121, 34-44 (2001).
2. Leung TWT, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5, 1676-1681 (1999).
3. Sato Y, Nakata K, Kato Y et al. Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N. Engl. J. Med 328(25), 1802-1806 (1993).
4. Poon TC, Mok TS, Chan AT et al. Quantification and utility of monosialylated α-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total α-fetoprotein. Clin. Chem. 48(7), 1021-1027 (2002).
5. Poon TC, Yip TT, Chan AT et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49(5), 752-760 (2003).
6. No authors listed. The new TNM classification in gastroenterology (1997). Endoscopy 30(7), 643-649 (1998).
7. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56, 918-928 (1985).
8. No authors listed. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28, 751-755 (1998)
9. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J. Hepatol. 31(1), 133-141 (1999).
10. Calvet X, Bruix J, Gines P et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12, 753-760 (1990).
11. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94(6), 1760-1769 (2002).